NeoPhore
About NeoPhore
NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Cancer neoantigens are known to stimulate the immune system and potentially be a weak spot in a tumour cell's defence mechanisms. The Company's approach targets genetic mechanisms that both clinical and lab studies suggest will promote neoantigen creation and diversity across numerous cancers. Using these insights, the Company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
YEAR FOUNDED:
2017
LEADERSHIP:
Chairman: Robert James
5 articles about NeoPhore
-
NeoPhore appoints Dr Matthew Baker as VP Immunology
7/8/2019
NeoPhore Limited, a small molecule cancer immuno-oncology company, announces the appointment of Dr Matthew Baker as VP Immunology to the company’s management team.
-
NeoPhore appoints Dr John Haurum as Non-Executive Director
3/20/2019
Former F-star CEO joins the Board of Directors
-
NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board
1/8/2018
NeoPhore today announced the formation of its Scientific Advisory Board, featuring internationally-renowned experts in the fields of cancer genetics, translational clinical oncology and immuno-oncology.
-
NeoPhore Scientific Founders Publish Breakthrough Immuno-Oncology Discoveries in Nature
11/30/2017
Clinical and now lab data suggest that many cancers with defective DNA repair appear to be highly sensitive to immune surveillance, including when the immune system is modified with agents that disrupt immune "checkpoints".
-
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company
11/15/2017
Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd